The US Food and Drug Administration (FDA) has approved Andexxa (coagulation factor Xa [recombinant] inactivated-zhzo) to reverse the anticoagulation effects of factor Xa inhibitors when needed due to ...

Factor Xa inhibitors are a type of anticoagulant, or blood thinner. They’re a short- and long-term therapy for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

SAN FRANCISCO, CA – A phase 3 study designed to test an antidote to the factor Xa inhibitor class of novel anticoagulants met its primary efficacy end point, according to an announcement from Portola ...

Despite considerable reductions in cardiovascular events in patients with an acute coronary syndrome (ACS) receiving dual antiplatelet therapy (DAPT), substantial residual risk persists. This unmet ...

If you live with atrial fibrillation (sometimes called AF or AFib), a type of irregular heartbeat, you probably take a blood thinner to reduce your risk of stroke and blood clots. Research shows that ...

New research by a team led by researchers from the Department of Cardiovascular Medicine at Tokyo Medical and Dental University (TMDU); and the Department of Cardiovascular Medicine at Tokyo Kyosai ...

ORLANDO, FL—A new interim analysis of the ongoing ANNEXA-4 study evaluating andexanet alfa (AndexXa; Portola Pharmaceuticals) affirms that the drug rapidly reverses the anticoagulant effects of the ...

Tissue factor initiates the extrinsic coagulation pathway by activating coagulation factor X to factor Xa, and factor V is a cofactor for the prothrombin activation by factor Xa. As factor Xa is known ...

Treatment with the bleeding reversal agent andexanet (Andexxa) in people with acute intracerebral hemorrhage on factor Xa inhibitors led to less expansion of hematoma volume but was associated with ...

Outcomes of temozolomide and capecitabine chemotherapy used in neuroendocrine and endocrine tumours: A real-world comparison of treatment evidence in Alberta, Canada, from 2011-2021. This is an ASCO ...

New research sheds light on the mechanism by which Rivaroxaban suppresses factor Xa and successfully attenuates atherosclerosis. New research by a team led by researchers from the Department of ...